According to a recent LinkedIn post from Antag Therapeutics, the company is scheduled to deliver both an oral and a poster presentation at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans. The post indicates that Chief Medical Officer Richard Nkulikiyinka will present first-in-human data on AT7687, described as a first-in-class GIPR antagonist peptide, in healthy subjects and individuals with obesity.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post also notes that Chief Scientific Officer Mads Tang-Christensen will present preclinical data on combining AT7687 with cagrilintide, a dual amylin and calcitonin receptor agonist with established weight-loss efficacy. For investors, these planned data disclosures at a major diabetes and obesity conference may signal clinical and scientific momentum around the AT7687 program, potentially supporting future partnering interest, validation of the mechanism, and the longer-term commercial prospects in the competitive obesity and metabolic disease market.